Last reviewed · How we verify
NCT05378282
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
trial in Type 2 Diabetes in 40 participants. Completed in 28 February 2023.
28 February 2023
Quick facts
| Lead sponsor | Hospital Juarez de Mexico |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 3 September 2021 |
| Primary completion | 28 February 2023 |
| Estimated completion | 28 February 2023 |
| Sites | 1 location across Mexico |
Conditions studied
- Type 2 Diabetes — all drugs for Type 2 Diabetes →
- Type 2 Diabetes With Renal Manifestations — all drugs for Type 2 Diabetes With Renal Manifestations →
Sponsor
Hospital Juarez de Mexico
Who can join
Adults 18 to 65, any sex, with Type 2 Diabetes or Type 2 Diabetes With Renal Manifestations. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
According to the different epidemiological studies in Mexico the prevalence of diabetic nephropathy is 9.1%-40% in diabetic patients, however the complication is subdiagnosed when we see the numbers of uncontrolled diabetics (75%) and patients that are under continuous screening to prevent complications development (only 12.6% had an annual albuminuria measurement). In addition, Mexican have an increased susceptibility to developing diabetic nephropathy. These data highlight the need to identify new biomarkers that could help us to identify those patients at high risk for developing diabetic nephropathy, in order to take preventing measures to delay the progress of the disease to CKD and improve the quality of the patients. Thus, the comparison of transcriptomic profile between diabetic patients with and without diabetic nephropathy is the first step to characterize this complication. In addition, we will be able to identify diabetic nephropathy biomarkers for development of new diagnostic tools and even to find therapeutic targets in Mexican from Hospital Juárez de México.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05378282
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Type 2 Diabetes
Currently open trials in the same condition.
- NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
- NCT07254689 — The Food for Health Study · NA · recruiting
- NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting
Other Hospital Juarez de Mexico trials
Trials by the same sponsor.
- NCT04164394 — Effect of I31 Probiotic on Lactose Intolerance · NA · completed
- NCT03945396 — Homeopathy for Overweight and Obesity in Mexican Adolescents · Phase 2 · unknown
- NCT04145856 — Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico · Phase 4 · completed
- NCT03849729 — Effectiveness and Tolerability of Phentermine in Patients Under Bariatric Surgery · Phase 4 · completed
- NCT04470791 — Cryotherapy as a Coadjuvant in Crotaline Snakebite Management With Antivenom. · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05378282 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital Juarez de Mexico
- Last refreshed: 28 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05378282.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing